Teva receives tentative approval for breast cancer drug

JERUSALEM The Food and Drug Administration has given tentative approval to Teva Pharmaceutical Industries for its generic version of a breast cancer treatment, the Israeli drug maker announced Thursday.

The agency gave Teva the tentative approval for letrozole tablets in the 2.5-mg strength, a generic version of Novartis’ Femara. Femara has annual sales of $556 million, according to IMS Health.

A tentative approval means that the generic drug meets the conditions for approval, but can’t be launched until the expiration of the patent, which will happen in June 2011.

Login or Register to post a comment.